Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Psychiatric disorders – page 24

  • 546 clinical trials
  • 252 recruiting
  • 147 conditions
  • 26 countries

Conditions in this area

147 conditions with trials, the busiest first

Dementia Alzheimer's type87Major depression57Schizophrenia39Depression35Narcolepsy19Cognitive disorder18Bipolar disorder16Autism spectrum disorder15Insomnia15Post-traumatic stress disorder14Psychotic disorder14Drug use disorder13Alcohol use disorder12Attention deficit hyperactivity disorder9Dementia9Obstructive sleep apnoea syndrome9Brain injury8Irritable bowel syndrome8Phenylketonuria8Bipolar I disorder7Drug dependence7Hypersomnia7Lennox-Gastaut syndrome7Anorexia nervosa6+123

Clinical trials in Psychiatric disorders

546 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

546 clinical trials

Alcoholism

Not yet recruiting

Effect of Hydroxocobalamin Acetate, Thiamine Hydrochloride, and Pyridoxine Hydrochloride Supplementation on Brain Injury in Outpatients with Alcohol Use Disorder

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Pyridoxine Hydrochloride
  • Sponsor:Inserm

Post-traumatic stress disorder

Not yet recruiting

Evaluation of Propranolol‑Enhanced Traumatic Memory Reactivation for Post‑Traumatic Stress Disorder in Women Victims of Violence

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Propranolol Hydrochloride
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Major depression

Not yet recruiting

Long‑Term Safety, Tolerability and Efficacy of Azetukalner in Patients with Major Depressive Disorder

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Narcolepsy

Not yet recruiting

A Randomized Double‑Blind Placebo‑Controlled Study of TAK‑360 in Adults with Narcolepsy with Cataplexy (Type 1)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Takeda Development Center Americas Inc.

Post-traumatic stress disorder

Not yet recruiting

Feasibility and Safety of PEX010 Psilocybin Capsules (5 mg and 25 mg) in Military Veterans with Posttraumatic Stress Disorder

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dry Extract From Psilocybe Cubensis (15-25:1), Extraction Solvent: Methanol
  • Sponsor:ARQ National Psychotrauma Centrum

Alcohol abuse

Not yet recruiting

Cannabidiol for Alcohol Dependence in Adults Seeking Abstinence: A Phase II Placebo‑Controlled Trial

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:CANNABINOL
  • Sponsor:Hospital Universitario 12 De Octubre

Schizophrenia

Not yet recruiting

Long-term safety and outcomes of repeated rituximab in adults with schizophrenia spectrum disorder

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Rituximab
  • Sponsor:Region Oerebro Laen

Substance use disorder

Not yet recruiting

Oxytocin Nasal Spray for Reducing Cravings and Preventing Relapse in Adults with Substance Use Disorder

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · Healthy volunteers
  • Substances:Oxytocin
  • Sponsor:Fondazione Santa Lucia

Attention deficit hyperactivity disorder

Not yet recruiting

Microdosing lysergide (20 µg) to improve symptoms, emotion regulation and sleep in adults with ADHD

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:LYSERGIDE
  • Sponsor:Universiteit Maastricht

Major depression

Not yet recruiting

Psilocybin and pimavanserin for adults with major depressive disorder

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Psilocybine
  • Sponsor:Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

Substance use disorder

Not yet recruiting

A study to evaluate the effects of rifaximin in patients with opioid use disorder

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Rifaximin
  • Sponsor:Fondazione Santa Lucia

Bipolar I disorder

Not yet recruiting

A study to evaluate the safety and effectiveness of azetukalner in patients with bipolar depression

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Substances studied in this area

The therapies tested most often in Psychiatric disorders trials.

Sodium Chloride25 clinical trialsTrospium Chloride17 clinical trialsXanomeline Tartrate16 clinical trialsCannabidiol15 clinical trialsDry Extract From Psilocybe Cubensis (15-25:1), Extraction Solvent: Methanol14 clinical trialsFlorquinitau (18F)14 clinical trialsOxytocin13 clinical trialsAripiprazole12 clinical trialsFlorbetaben (18F)12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.